Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Meyer Characterizes Current Approaches to Diagnosing, Managing, and Studying Cardiac Angiosarcoma

January 10th 2022

Dr Meyer discusses the rarity of cardiac angiosarcoma, optimizing detection strategies, surgical interventions, and chemotherapy for this patient population, and why immunotherapy has the potential to transform care for patients.

Devimistat Plus Hydroxychloroquine Shows Early Promise in Relapsed Clear Cell Sarcoma

January 7th 2022

No dose-limiting toxicities have been reported in the first cohort of patients with relapsed clear cell sarcoma who received the combination of devimistat and hydroxychloroquine in the dose-escalation portion of the ongoing phase 1/2 APOLLO 613 trial.

Dr. Randall on Preventing Early Failures With Osseointegrated Endoprostheses in Bone Sarcomas

January 6th 2022

R. Lor Randall, MD, FACS, discusses methods of preventing early failures with compressive osseointegrative endoprosthetic devices of the femur in bone sarcomas.

Olaparib/Temozolomide Shows Encouraging Efficacy, Manageable Safety in Uterine Leiomyosarcoma

January 5th 2022

In patients with advanced uterine leiomyosarcoma whose tumors harbor a BRCA-like phenotype, the combination of olaparib with temozolomide could represent a new standard of care.

FDA Grants Rare Pediatric Disease Designation for IMX-110 for Rhabdomyosarcoma

January 4th 2022

The FDA has granted a rare pediatric disease designation to IMX-110 for the treatment of rhabdomyosarcoma.

Putting the Extremely Rare Cardiac Angiosarcoma in the Spotlight

December 21st 2021

Cardiac angiosarcoma is an exceptionally rare cancer that has become national news because of the recent death of acclaimed fashion designer, Virgil Abloh. He was 41 years old when he died in November 2021, following a 2-year battle with the disease, which is an aggressive subtype of soft-tissue sarcoma.

Current Management Strategies for Desmoid Tumors Are Marked by Less Surgery, More Systemic Options

December 20th 2021

Despite their rarity, the management of desmoid tumors has been an area of significant clinical change as the field has shifted away from aggressive surgical interventions to active surveillance and systemic therapies that are less morbid for patients.

Enrollment in Histologically-Specific Trials Improves Outcomes in Soft Tissue Sarcoma

December 16th 2021

Elise Nassif, MD, discusses the evolving standard of care for patients with soft tissue sarcoma and the benefits of early phase inclusion, as well as histotype testing for this population.

VTC Plus Standard Chemotherapy Fails to Improve EFS and OS in Ewing Sarcoma

December 16th 2021

R. Lor Randall, MD, FACS, elaborates on the results of a study and provided insight into future research directions in Ewing sarcoma

Dr. Randall on the Evolution of Limb Salvage Technologies in Bone Sarcomas

December 10th 2021

R. Lor Randall, MD, FACS, discusses the evolution of limb salvage technologies in bone sarcomas.

Ribociclib/Everolimus Elicits Responses in Dedifferentiated Liposarcoma

December 5th 2021

Margaret von Mehren, MD, discusses the value of ribociclib plus everolimus for patients with dedifferentiated liposarcoma, and how further research will be focused on biomarker analysis.

ONCT-216 Shows Encouraging Efficacy, Safety in Relapsed/Refractory Ewing Sarcoma

November 24th 2021

The targeted small molecule inhibitor of the E26 transformation-specific family of oncoproteins, ONCT-216, produced notable response and disease control rates when delivered at the recommended phase 2 dose to heavily pretreated patients with Ewing sarcoma.

FDA Approves Sirolimus Protein-Bound Particles for Malignant PEComa

November 23rd 2021

The FDA has approved sirolimus albumin-bound particles for injectable suspension for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor.

Dr. Wilky on the Diagnosis and Management of Desmoid Tumors

November 19th 2021

Breelyn Wilky, MD, discusses the diagnosis and management of desmoid tumors.

NBTXR3 Plus Radiotherapy Maintains Safety, Quality of Life in Soft Tissue Sarcoma

November 19th 2021

Sylvie Bonvalot, MD, PhD, HDR, discusses the long-term safety results from the phase 2/3 Act.In.Sarc trial with NBTXR3 and radiotherapy in patients with soft tissue sarcoma.

Compressive Osseointegrated Endoprostheses Provide Long-Term Benefit in Bone Sarcoma

November 18th 2021

R. Lor Randall, MD, FACS, the 10-year results of a retrospective analysis, potential strategies to mitigate early failures in recipients of compressive osseointegrative endoprosthetic devices, and the need for communication between medical oncologists and orthopedic surgeons to ensure patients on chemotherapy receive optimal care.

Dr. D’Amato on Optimizing Treatment for Patients With Desmoid Tumors

November 18th 2021

Gina Z. D’Amato, MD, discusses optimizing treatment for patients with desmoid tumors.

Dr. Riedel on the Challenges of Diagnosing and Treating Patients With Desmoid Tumors

November 18th 2021

Richard F. Riedel, MD, discusses the challenges of diagnosing and treating patients with desmoid tumors.

Ripretinib Continues to Provide Meaningful Clinical Benefit in Heavily Pretreated GIST

November 10th 2021

John R. Zalcberg, MBBS, PhD, discusses the INVICTUS trial examining ripretinib in patients with heavily pretreated gastrointestinal stromal tumors, the impact of the agent on the paradigm, and ongoing efforts to provide additional options to this population.

Pembrolizumab/Lenvatinib Combo Under Investigation in Classic Kaposi Sarcoma

November 9th 2021

Alice Indini, MD, discusses the ongoing PULSAR trial examining pembrolizumab plus lenvatinib as a novel therapeutic option for patients with classic Kaposi sarcoma.